CPRXNEUTRAL

Gross Margin

90.3%

Higher than 95% of Healthcare sector peers

Updated 189h ago

Sector Performance

95th percentile

CPRX

90.3%

Sector Median

68.9%

Sector Avg

-20.2%

📊

Deep Analysis

A gross margin of 90.3% means that for every dollar of sales, Catalyst Pharmaceuticals keeps about 90.3 cents after covering the direct cost of producing its drugs.

This is well above the healthcare sector median of 68.9%, placing the company in the 95th percentile among its peers. The year-over-year change is not available, and the quarter-over-quarter change is also not available, so no trend direction can be assessed from the last eight quarters. The high absolute margin suggests strong pricing power and low production costs, but the lack of trend data leaves uncertainty about whether this level is stable or eroding. Given the neutral verdict on the stock, the outstanding margin alone does not contradict that view, as margin strength is already priced in and offset by other factors not captured here.

Frequently Asked Questions

What does the Gross Margin tell investors about CPRX?

Gross margin reveals pricing power and cost structure. Software companies often sustain 70–80%; manufacturers typically 30–50%. Expansion is a bullish signal.

How is the Gross Margin calculated?

Gross Margin is calculated as: Gross Profit / Revenue.

How does CPRX's Gross Margin compare to its sector?

CPRX's Gross Margin of 90.3% compares to a Healthcare sector median of 68.9%, placing it in the 95th percentile.

Who are CPRX's closest peers by Gross Margin?

The closest Healthcare peers by Gross Margin include: AMGN (68.2%), TDOC (67.8%), TECH (66.9%), NTRA (64.8%), RMD (62.2%).

The Formula

Gross Profit / Revenue

Why It Matters

Gross margin reveals pricing power and cost structure. Software companies often sustain 70–80%; manufacturers typically 30–50%. Expansion is a bullish signal.